Dissecting mechanisms by which mRNA vaccines encoding nontumor antigens initiate antitumor immunity
About This Grant
Immune checkpoint inhibitors (ICIs) have significantly improved survival in many cancer patients, but most still fail to respond to these treatments. We and others have demonstrated that personalized mRNA lipid nanoparticle vaccines enhance antitumor immunity in combination with PD-1 inhibition. However, we recently found that mRNA vaccines targeting non-tumor antigens can also act as potent adjuvants to immune checkpoint blockade, leading to improved survival in non-small cell lung cancer and metastatic melanoma patients. This proposal aims to interrogate the mechanisms by which mRNA vaccines targeting non-tumor antigens generate antitumor immunity. Our overarching hypothesis is that much of the benefit of personalized mRNA vaccines is derived from their ability to broaden the T cell repertoire by enhancing DC priming of T cells in tumors and tdLNs, leading to antitumor immunity that is most magnified by CTLA-4 blockade. We will test this hypothesis through three specific aims: Aim 1: Determine the mechanism by which non-neoantigen mRNA vaccines produce tumor-reactive T cells. Aim 2: Dissect the mechanism by which mRNA vaccines preferentially augment antitumor responses to CTLA-4 blockade. Aim 3: Interrogate the importance of antigen selection for mRNA cancer vaccines in combination with PD-1 and CTLA-4 blockade. This study is designed to offer a transformational shift in our understanding of mRNA vaccines, highlighting their potential not only as tumor-targeting agents but also as powerful adjuvants for immune checkpoint blockade. Ultimately, this research aims to leverage the innate adjuvanticity of mRNA to facilitate the development of universal cancer vaccines.
Grant Summary
Dissecting mechanisms by which mRNA vaccines encoding nontumor antigens initiate antitumor immunity is a NCI - National Cancer Institute grant providing up to $136K for university, nonprofit, healthcare org. Applications are due 2031-05-31 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $136K
2031-05-31
- 1Confirm your organization is eligible for Dissecting mechanisms by which mRNA vaccines encoding nontumor antigens initiate antitumor immunity from NCI - National Cancer Institute, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NCI - National Cancer Institute before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NCI - National Cancer Institute's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Dissecting mechanisms by which mRNA vaccines encoding nontumor antigens initiate antitumor immunity: Frequently Asked Questions
Who is eligible for the Dissecting mechanisms by which mRNA vaccines encoding nontumor antigens initiate antitumor immunity?
Dissecting mechanisms by which mRNA vaccines encoding nontumor antigens initiate antitumor immunity is offered by NCI - National Cancer Institute and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Dissecting mechanisms by which mRNA vaccines encoding nontumor antigens initiate antitumor immunity provide?
Dissecting mechanisms by which mRNA vaccines encoding nontumor antigens initiate antitumor immunity provides up to $136K per award from NCI - National Cancer Institute. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Dissecting mechanisms by which mRNA vaccines encoding nontumor antigens initiate antitumor immunity deadline?
Applications for Dissecting mechanisms by which mRNA vaccines encoding nontumor antigens initiate antitumor immunity are due 2031-05-31 (open). Because deadlines can change, verify the date with the funder, NCI - National Cancer Institute, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Dissecting mechanisms by which mRNA vaccines encoding nontumor antigens initiate antitumor immunity?
To apply for Dissecting mechanisms by which mRNA vaccines encoding nontumor antigens initiate antitumor immunity, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NCI - National Cancer Institute.